WO2025141521 - LIPIDS HAVING DENDRITIC MOIETIES

National phase entry is expected:
Publication Number WO/2025/141521
Publication Date 03.07.2025
International Application No. PCT/IB2024/063236
International Filing Date 27.12.2024
Title **
[English] LIPIDS HAVING DENDRITIC MOIETIES
[French] LIPIDES COMPORTANT DES FRACTIONS DENDRITIQUES
Applicants **
SANOFI
Inventors
BAZIN, Emilie
DRIGUEZ, Pierre Alexandre
GARINOT, Marie
KARST, Nathalie
RUIZ, Sophie
VAURE, Celine
Priority Data
23307434.3   29.12.2023   EP
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
译文

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting6604
EPO Filing, Examination, Granting26238
Japan Filing, Examination, Granting2494
South Korea Filing, Examination, Granting2763
USA Filing, Examination, Granting12540
MasterCard Visa
Total: 50,639
Contact Us
Abstract[English] Provided herein are dendritic lipids or pharmaceutically acceptable salts thereof. The dendritic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.[French] L'invention concerne des lipides dendritiques ou leurs sels pharmaceutiquement acceptables. Les Iipides dendritiques de l'invention peuvent être utiles pour la délivrance et l'expression d'ARNm et de protéine codée, par exemple, en tant que constituant d'un véhicule de délivrance liposomale, et peuvent par conséquent être utiles pour traiter divers maladies, troubles et affections, comme ceux associés à un déficit en une ou plusieurs protéines.